News

Early lab trials using a new research-based treatment for the prevention of peanut allergy are showing the potential for it to be an effective preventative for peanut-specific allergic responses. The new treatment, referred to as ‘Covalent heterobivalent inhibitor’ (cHBI), works…

People with coeliac disease have been found to have a higher chance of having heart disease compared to those without coeliac disease. The findings come from a study using data from the UK Biobank, a large database of health information,…

The prevalence of allergic diseases in the Middle East Region is said to be rapidly increasing, while food allergy knowledge in the population is lacking. Recent studies have delved deeper into prevalence and knowledge of food allergies in Saudi Arabia.…

To ensure that VITAL Online remains up to date with best practice technology the Allergen Bureau will shortly be introducing multifactor authentication to your VITAL Online log in. Just like your banking system, by using recognised Authenticators like Google Authenticator…

Aravax is a Melbourne-based biotechnology company developing the first precisely targeted immunotherapeutic for peanut allergy, PVX108. An investment of US$20m from Australian investors, Brandon Capital and Tenmile will support Phase 2 trials. PVX108 does not contain peanut protein but is…

Cowpea (Vigna unguiculata) is a legume that is widely cultivated and very important for the nutrition and health of millions of people, particularly in Africa, Asia, South America, and Southern Europe. Cowpea is emerging as a low-cost alternative protein in…